Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImQuest Pharmaceuticals has entered into a collaboration agreement with Korea's Samjin Pharmaceutical Co which will be initially focused on the development of agents for the treatment of infectious disease and cancer.
Subscribe to our email newsletter
In the collaboration ImQuest will provide complete preclinical and clinical drug development support for therapeutic small molecules discovered by Samjin Pharmaceutical.
“This relationship merges the significant individual strengths of both companies,” commented Jerry Cartright, ImQuest Pharmaceuticals’ CEO. “Samjin’s medicinal chemistry team will provide new entities that will be developed using ImQuest’s preclinical and clinical development expertise.”
ImQuest is a US based developer of novel therapeutic agents for the treatment of infectious disease, cancer and inflammatory disease, with lead candidates for HIV therapy and microbicide treatment in late preclinical development. Samjin is one of the leading pharmaceutical companies in Korea with projected sales for 2005 estimated at $120 million.